Resilient CSL enters new growth phase

Australia’s homegrown biotech giant CSL has reported a 36 per cent surge in plasma collection volumes to a record high, helping drive a 19 per cent jump in revenue, as its core business shines through as the ongoing growth engine of the $150 billion company. CSL pointed to increased demand for its core immunoglobulin-based therapies […]